Tags

Type your tag names separated by a space and hit enter

Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
Viruses. 2021 03 05; 13(3)V

Abstract

The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in CYP3A4, CYP3A5, CYP2C8, CY2D6, ABCB1, ABCC2, and SLCO1B1, among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug-drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19.

Authors+Show Affiliations

HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33807592

Citation

Fricke-Galindo, Ingrid, and Ramcés Falfán-Valencia. "Pharmacogenetics Approach for the Improvement of COVID-19 Treatment." Viruses, vol. 13, no. 3, 2021.
Fricke-Galindo I, Falfán-Valencia R. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses. 2021;13(3).
Fricke-Galindo, I., & Falfán-Valencia, R. (2021). Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses, 13(3). https://doi.org/10.3390/v13030413
Fricke-Galindo I, Falfán-Valencia R. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses. 2021 03 5;13(3) PubMed PMID: 33807592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. AU - Fricke-Galindo,Ingrid, AU - Falfán-Valencia,Ramcés, Y1 - 2021/03/05/ PY - 2021/01/27/received PY - 2021/02/22/revised PY - 2021/03/01/accepted PY - 2021/4/3/entrez PY - 2021/4/4/pubmed PY - 2021/4/20/medline KW - ABCB1 KW - COVID-19 KW - CYP2D6 KW - CYP3A4 KW - NR1I2 KW - pharmacogenetics JF - Viruses JO - Viruses VL - 13 IS - 3 N2 - The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in CYP3A4, CYP3A5, CYP2C8, CY2D6, ABCB1, ABCC2, and SLCO1B1, among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug-drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/33807592/Pharmacogenetics_Approach_for_the_Improvement_of_COVID-19_Treatment. L2 - https://www.mdpi.com/resolver?pii=v13030413 DB - PRIME DP - Unbound Medicine ER -